Advances in structure-based drug design of novel bacterial topoisomerase inhibitors

Future Medicinal Chemistry

Volumn 2, Issue 11, 2010, Pages 1619-1622

  Widdowson, Katherine ^a   Hennessy, Alan ^b  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

antibacterial mode of action; bacterial topoisomerase inhibitors; novel bacterial topoisomerase inhibitors; quinolone antibacterials; treatment of resistant bacterial infection; X ray structure based drug design

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; GSK 299423; MOXIFLOXACIN; NXL 101; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG; VIQUIDICIN;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; CRYSTAL STRUCTURE; DNA BINDING; DRUG DESIGN; DRUG POTENCY; DRUG WITHDRAWAL; EDITORIAL; GENE MUTATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; QT PROLONGATION; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION;

BACTERIAL PROTEINS; DNA; DNA GYRASE; DRUG DESIGN; HUMANS; QUINOLONES; TOPOISOMERASE INHIBITORS;

EID: 78649309791     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.250     Document Type: Editorial

References (14)

1. Mitcher LA. Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents. Chem. Rev. 105(2), 559-592 (2005).
2. Gellert M, Mizuuchi K, O'Dea MH, Nash HA. DNA gyrase: an enzyme that introduces superhelical turns into DNA. Proc. Natl Acad. Sci. USA 73(11), 3872-3876 (1976).
3. Cozzarelli NR. DNA gyrase and the supercoiling of DNA. Science 207(4434), 953-960 (1980).
4. Drevensek P, Kosmrlj J, Giester G et al. X-ray crystallographic, NMR and antimicrobial activity studies of magnesium complexes of fuoroquinolones - racemic ofoxacin and its S-form, levofoxacin. J. Inorg. Biochem. 100(11), 1755-1763 (2006).
5. Edwards MJ, Flatman RH, Mitchenall LA et al. A crystal structure of the bifunctional antibiotic simocyclinone D8, bound to DNA gyrase. Science 326(5958), 1415-1418 (2009).
6. Laponogov IS, Sohi MK, Veselkov DA et al. Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat. Struct. Mol. Biol. 16(6), 667-669 (2009).
7. Laponogov I, Pan X, Veselkov DA et al. Structural basis of DNA-gate breakage and resealing by type II topoisomerases. PLoS ONE 5(6), 1-8 (2010).
8. Wohlkonig A, Chan PF, Fosberry AP et al. Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat. Struct. Mol. Biol. 17(9), 1152-1153 (2010).
9. Bax BD, Chan PF, Eggleston DS et al. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466(19), 935-940 (2010).
10. Gomez L, Hack MD, Wu J et al. Novel pyrazole derivatives as potent inhibitors of type II topoisomerases. Part 1: synthesis and preliminary SAR ana lysis. Bioorg. Med. Chem. Lett. 17(10), 2723-2727 (2007).
11. Wiener JJM, Gomez L, Venkatesan H et al. Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains. Bioorg. Med. Chem. Lett. 17(10), 2718-2722 (2007).
12. Black MT, Stachyra T, Platel D et al. Mechanism of action of the antibiotic NXL101, a novel nonfuoroquinolone inhibitor of bacterial type II topoisomerases Antimicrob. Agents. Chemother. 52(9), 3339-3349 (2008).
13. Black MT, Stachyra T, Platel D et al. New inhibitors of bacterial topoisomerase GyrA/ParC subunits Curr. Opin. Invest. Drugs 10(8), 804-810 (2009).
14. Jeffrey GA, Saenger W. Hydrogen Bonding in Biological Structures. Springer, NY, USA (1991).